@entity6371 ( @entity6371 ) is often used for the treatment of highly experienced @entity1 who harbor @entity645 variants with decreased susceptibility to multiple antiretrovirals. @entity1 on @entity6371 typically have limited treatment options, and without treatment, their prognosis can be poor. Yet the decision to go on @entity6371 is not always straightforward as @entity6371 can be associated with significant challenges including multiple daily doses, higher pill burden, emerging @entity137 , and drug interactions. All of these may compromise adherence, which is often a major reason why @entity1 may need @entity6371 in the first place. Little is known about how @entity1 and health care providers (HCPs) experience @entity6371 . This study sought to explore areas of convergence and divergence between @entity1 and HCPs in order to identify gaps in treatment and factors that may impact adherence to @entity6371 . A qualitative interview method based on grounded theory was used. Twelve @entity1 and seven HCPs completed a 60-minute semistructured interview. @entity1 were asked about challenges, facilitative aspects of staying on @entity6371 , the decision to initiate treatment, their role, and the role of HCPs in their health care. HCPs were asked about their experience working with @entity6371 @entity1 , their role, and the role of the @entity1 . Congruent themes emerged from the two groups: developing a working relationship, treatment factors, information requirements, and readiness for treatment. There were no discrepancies in role perspectives. @entity1 and HCPs agreed on the need to optimize @entity1 ' readiness, willingness, and ability to embark on @entity6371 to maximize adherence. HCPs assumptions about beginning @entity6371 based solely on medical indications must be checked and discussed to ensure @entity1 ' motivation. In conclusion, adherence to @entity6371 demands a substantial behavior change, recognized as a major challenge by @entity1 . Allocating the time to make a commitment to treatment can optimize adherence. It is therefore crucial that @entity1 be provided with time to make informed decisions, explore and resolve their willingness and readiness to commit to treatment, and maintain supportive relationships with their HCPs, all of which can optimize adherence to @entity6371 .

Psychosocial issues influencing treatment adherence in @entity1 on multidrug rescue therapy: perspectives from XXXX and their health care providers.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity6371 :: ('MESH:D018088', 'Disease') :: ['MDRT', 'Multi-drug rescue therapy'] @entity645 :: ('57667', 'Species') :: ['HIV'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']
@entity1 :: (9606,Species) :: ['patients']
